Radioactive therapy takes aim at Hard-to-Treat kidney cancer

NCT ID NCT06964958

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a radioactive drug called 177Lu-PSMA-617 (Pluvicto) in 24 people with advanced clear cell kidney cancer that shows a specific marker (PSMA). The drug is given by IV and aims to shrink tumors. Researchers are measuring how many patients respond and tracking side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-617 (Pluvicto), a radioactive drug given by IV
What this could lead to: If successful, this could offer a new treatment option for advanced kidney cancer that has not responded to other therapies.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Radioactive drugs can cause side effects like fatigue, low blood counts, or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CLEAR CELL RENAL CELL CARCINOMA KIDNEY CANCER RENAL CELL CARCINOMA

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.